
Crosslink Capital increased its monday.com position by 143,650 shares in Q3 (per a Nov. 14, 2025 SEC filing), bringing its total holding to 203,865 shares with a market value of $39.49 million as of Sept. 30, 2025 (2.87% of $1.37B reportable U.S. equity assets). Monday.com shares trade at $156.98 and are down ~46% Y/Y; the company reports TTM revenue of $1.2B and net income of $65M, with recent quarter revenue growth of ~26% and a 117% net retention rate among larger customers. The filing coincides with Crosslink downsizing overall AUM by 22% during the quarter; the purchase is framed as a buy-the-dip by analysts who also note a FCF multiple near 24x (rising to ~48x including stock-based comp) and potential upside from AI-infused product adoption.
Market structure: Crosslink’s buy (143,650 shares, bringing its MNDY stake to ~203,865 shares, $39.5m) signals selective value-hunting into a name down ~46% YTD with $8.1bn market cap and $1.2bn TTM revenue. Direct winners are AI/automation-enabled collaboration vendors (MNDY, VEEV) capturing incremental enterprise spend; losers are narrower point solutions and legacy on‑prem tools losing pricing power to modular Work OS platforms. The immediate supply/demand imbalance is driven by fund-level selling (Crosslink trimmed AUM 22%) rather than deteriorating fundamentals — transient selling pressure can keep volatility elevated even as underlying demand (NRR 117% for large clients) remains strong. Risk assessment: Tail risks include material worsening of net retention (NRR decline <110%), sharp rise in stock‑based comp (SBC) that doubles adjusted valuation (current FCF multiple 24x vs ~48x including SBC), or an enterprise IT spending shock from a macro slowdown. Near-term (days–weeks) expect headline-driven swings around 13F and earnings; medium-term (3–9 months) the cadence of product AI rollouts and NRR trends will drive re-rating; long-term (12–36 months) hinges on sustained FCF conversion and SBC discipline. Hidden dependency: price action is sensitive to large fund flows — Crosslink’s outsized concentration in CHYM (42.9% AUM) raises chance of future forced rebalancing. Trade implications: Preferred direct play is a staggered long MNDY position (build to 2–3% portfolio) with tranches: 1% at market, +1% if < $140, +1% if < $120; hard stop at -25% from entry. Pair trade: long MNDY vs short TEAM (Atlassian) sized 1:0.7 to capture sharper re‑acceleration in upsells; short candidate if Atlassian NRR slips below 105%. Options: buy a 9‑ to 12‑month call spread (e.g., Sep‑2026 170/260) to cap premium while retaining upside if AI adoption accelerates and FCF margin >8% by next fiscal year. Contrarian angles: Consensus underestimates SBC drag and overweights the “cheap FCF” narrative — adjusted multiples imply limited margin of safety unless SBC falls materially. Crosslink buying while shrinking AUM is ambiguous: it can be genuine conviction or opportunistic window‑dressing; price could still fall if broader tech deleveraging resumes. Historical parallels (post‑selloff recoveries in collaboration SaaS) show >50% recoveries are possible when NRR stays >115% and FCF conversion improves; monitor quarterly NRR, SBC run‑rate, and FCF margin — if NRR <110% or FCF margin <5%, re‑evaluate downsize/exit within 30 days.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment